Australia · Delayed Price · Currency is AUD Clinuvel Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Delivered a 10th consecutive year of profit, with revenue surpassing AUD 100 million and strong margins. Announced plans to delist from ASX and list on Nasdaq, focusing on U.S. growth and expanding R&D in vitiligo and peptide platforms. Cash reserves rose to AUD 252 million.
-
Revenue grew 4% year-over-year to a record high, with profitability maintained despite a 22% rise in expenses driven by R&D and expansion. Cash reserves reached AUD 233 million, supporting self-funded growth and upcoming catalysts like clinical trial readouts and Nasdaq listing.
Fiscal Year 2025
-
Reported ninth consecutive annual profit with 10% revenue growth to $105M and a 34% net margin. Cash reserves rose 22%, supporting robust R&D and expansion, while the EPP and vitiligo markets continue to grow. Major clinical and regulatory milestones are expected in the coming year.
-
Half-year results showed strong revenue and profit growth, with robust cash reserves and continued expansion in key markets. Investment in late-stage clinical programs is set to rise, while a prudent capital management approach supports future growth and resilience.
Fiscal Year 2024
-
The meeting highlighted record financial results, strong cash reserves, and ongoing diversification into new therapies and photocosmetics. Key priorities include CEO succession, expanding the board, advancing vitiligo trials, and leveraging marketing to boost visibility and growth.
-
Record revenue and profit growth driven by Scenesse sales and expansion in North America, with robust margins and a strong balance sheet. Ongoing investments in R&D, photocosmetics, and talent support future growth, while the company remains debt-free and continues dividends.